Abstract
Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm occasionally presenting with features of leukostasis as primary symptoms. Hearing loss is occasionally reported in CML patients. Further whether Imatinib mesylate has any effect on vestibular functions is not known. We conducted a preliminary study to assess hearing pattern in patients with CML on long term TKI therapy. This is a single center, cross sectional study from northern-India. Patients of CML who were on regular Tyrosine kinase inhibitors (TKI) therapy for at least 6 months underwent audiovestibular evaluation . A total of 44 CML patients on TKI therapy were assessed over a period of 6 months. The median age of the patients was 41 years, the mean duration of TKI therapy was 36 months. Four patients were found to have otological disorder clinically. On pure tone audiometry of 88 ears normal hearing pattern were found with at low and mid frequencies. There was a down sloping type of curve at higher frequencies in PTA in most of the patients. Cold caloric tests in 42 patients were found as equal response in both ears. We conclude from this preliminary study that there are no audio vestibular dysfunctions amongst patients of CML on TKI. It’s a negative study wherein we have ruled out any auditory deficits secondary to Imatinib therapy. Further studies are required to evaluate the audiometric profile in CML patients before Imatinib therapy and to be compared with the patients already on Imatinib in a large cohort.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Mahon FX, Reiffers J (1996) Leucemie myeloide chronique. Rev Prat 46:2232–2234
Ejele OA, Omunakwe HE, Lyalla C, Da Lilly-Tariah OB, Pedro-Egbe CN (2013) Visual and auditory complications of chronic myeloid leukemia: a case report. Br J Med Med Res 3(3):566–572
Donne A (1844) Cours de microscopic complementaire des etudes medicales, anoyomie, microscopiqueet, physiologie des fluides de l’economic. JB Bailliere, Paris
Vidal E (1856) De la leucocythemiesplenique, ou de l’hypertrophie de la rate avec alteration du sang consistant dans une augmentation considerable du nombre blancs. Gaz Hebd Sci Med Bordeaux 3:166,201,235
Politzer A (1885) Pathologische Veranderungen im Labyrinthe bei leukamischer Taubheit. Cong Int Otol 3:139
Genden EM, Bahdori RS (1995) Bilateral sensorineural hearing loss as a first symptom of chronic myelogenous leukemia. Otolaryngol Head Neck Surg 113:499–501
Cherchi M, Huo E, Nelson N et al (2006) Gradual hearing loss with bilateral labyrinthine haemorrhage in chronic myelogenous leukemia. Neurology 67:177–178
Chae SW, Cho JH, Lee JH, Kang HJ, Hwang SJ (2002) Sudden hearing loss in chronic myelogenous leukaemia implicating the hyperviscosity syndrome. J Laryngol Otol 116(04):291–293
Hsu YC, Su CY, Hsu RF (2004) Unilateral sudden hearing loss as a presenting manifestation of chronic myeloid leukemia: case report. Otolaryngol Head Neck Surg 130:271–273
Acar GO, Aciglu E, Enver O et al (2007) Unilateral sudden hearing loss as the first sign of chronic myeloid leukemia. Eur Arch Otorhinolaryngol 264(12):1513–1516
Pochedly C (1969) Unusual manifestations of chronic granulocytic leukemia in a child. Cancer 24(5):1017–1020
Vidal E (1856) De la leucocythemiesplenique, ou de l’hypertrophie de la rate avec alteration du sang consistantdansune augmentation considerable du nombreblancs. Gaz Hebd Sci Med Bordeaux 3:166
Politzer A (1885) PathologischeVeranderungenim Labyrinthe bei leukamischer Taubheit. Cong Int Otol 3:139
Druss J (1945) Aural manifestations of leukemia. Arch Otolaryngol 42:267
Naithani R, Chandra J, Mathur NN et al (2005) Hearing loss in chronic myeloid leukemia. Pediatr Blood Cancer 45:54–55
Resende LSR, Coradazzi AL et al (2000) Sudden bilateral deafness from hyperlukocytosis in chronic myeloid leukemia. Acta Haematol 104:46–49
Preston FE, Sokol RJ, Lilleyman JS, Winfield DA et al (1978) Cellular hyperviscosity as a cause of neurological symptoms in leukemia. Br Med J 25:476–478
Attili VS, Bapsy PP, Anupama G, Lokanatha D (2008) Irreversible sensorineural hearing loss due to Imatinib. Leuk Res 32(6):991–992. doi:10.1016/j.leukres.2007.11.039
Janssen JJ, Berendse HW, Schuurhuis GJ, Merle PA, Ossenkoppele GJ (2009) A 51-year-old male CML patient with progressive hearing loss, confusion, ataxia, and aphasia during imatinib treatment. Am J Hematol 84:679–682
Lin HW, Roberts DS, Kay J, Stankovic KM (2012) Sensorineural hearing loss following imatinib (Gleevec) administration. Otolaryngol Head Neck Surg 146(2):335–337. doi:10.1177/0194599811415008
Fritzsch B, Pirvola U, Ylikoski J (1999) Making and breaking the innervation of the ear: neurotrophic support during ear development and its clinical implications. Cell Tissue Res 295:369–382
Petit C (1996) Genes responsible for human hereditary deafness: symphony of a thousand. Nat Genet 14:385–391
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
None.
Rights and permissions
About this article
Cite this article
Gupta, R., Yanamandra, U., Gupta, B. et al. Audio Vestibular Status in CML Patients on Imatinib Mesylate with Review of Literature. Indian J Hematol Blood Transfus 33, 175–180 (2017). https://doi.org/10.1007/s12288-015-0612-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12288-015-0612-4